Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)

NCT01297270 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

658

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C

Interventions

DRUG: BI201335
DRUG: PegIFN/RBV
DRUG: BI201335
DRUG: Placebo

Sponsor

Boehringer Ingelheim